Ibrutinib for Chronic Graft versus Host Disease


( Last Updated : June 24, 2022)
Project Line:
Health Technology Review
Project Sub Line:
Summary with Critical Appraisal
Project Number:
RC1433-000

Details


Question

  1. What is the clinical effectiveness of ibrutinib in patients with chronic graft-versus-host disease who have inadequate response to corticosteroids or other systemic therapies?

Key Message

No eligible evidence was identified comparing ibrutinib to another intervention for the management of treatment-refractory chronic graft-versus-host disease.

Currently available evidence describing second- or third-line therapies for treatment-refractory chronic graft-versus-host disease was ineligible for this review because of the use of non-comparative research methods (i.e., single-arm trials, case series, and case reports).

One randomized controlled trial is currently under way investigating the use of ibrutinib as first-line therapy for chronic graft-versus-host disease; however, no randomized controlled trials of ibrutinib for the management of treatment-refractory chronic graft-versus-host disease are currently being conducted.

The need for high-quality randomized controlled trials of ibrutinib for treatment-refractory chronic graft-versus-host disease has been highlighted repeatedly in recent literature.